139 related articles for article (PubMed ID: 8981333)
1. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
[TBL] [Abstract][Full Text] [Related]
3. OESCLIM: an advanced delivery system for HRT.
Munoz A
Maturitas; 1999 Nov; 33 Suppl 1():S39-47. PubMed ID: 10661614
[TBL] [Abstract][Full Text] [Related]
4. OESCLIM: pre-clinical and clinical profile.
Guy M
Maturitas; 1999 Nov; 33 Suppl 1():S49-55. PubMed ID: 10661615
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
Erianne JA; Winter L
Maturitas; 1997 Mar; 26(2):95-101. PubMed ID: 9089558
[TBL] [Abstract][Full Text] [Related]
7. OESCLIM: summary of tolerability and safety.
Brackman F
Maturitas; 1999 Nov; 33 Suppl 1():S83-8. PubMed ID: 10661619
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
Gordon SF
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
[TBL] [Abstract][Full Text] [Related]
9. A randomised study to compare the efficacy and safety of new 17 beta-oestradiol transdermal matrix patch with Estraderm TTS 50 in hysterectomised postmenopausal women. The Lyrelle Study Group.
al-Azzawi F; Van der Mooren MJ; Rolland R; Hirvonen E
Br J Clin Pract; 1997; 51(1):20-3, 25-6. PubMed ID: 9158267
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of low-dose transdermal estrogen (Oesclim) in the treatment of menopausal symptoms.
Gadomska H; Barcz E; Cyganek A; Leocmach Y; Chadha-Boreham H; Marianowski L
Curr Med Res Opin; 2002; 18(2):97-102. PubMed ID: 12017217
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.
Paoletti AM; Pilia I; Nannipieri F; Bigini C; Melis GB
Maturitas; 2001 Dec; 40(3):203-9. PubMed ID: 11731181
[TBL] [Abstract][Full Text] [Related]
12. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of climacteric syndrome using Estraderm TTS and premarin in a comparative study].
Leodolter S; Sainz H; Moll-Schüler I; Mach R
Gynakol Geburtshilfliche Rundsch; 1992; 32(4):201-4. PubMed ID: 1337708
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems.
Guichard JP; Sauron R; Jones AB
J Clin Pharmacol; 1999 Aug; 39(8):811-6. PubMed ID: 10434233
[TBL] [Abstract][Full Text] [Related]
16. [Transdermal administration of estrogens in women with the postcastration and climacteric syndromes].
Rotta L; Matĕchová E
Cesk Gynekol; 1992 Sep; 57(7):336-40. PubMed ID: 1394497
[TBL] [Abstract][Full Text] [Related]
17. The long-term tolerability and efficacy of OESCLIM: results of a 1-year study.
Taurelle R; L'Hermite M; Haenggi W; Lauritzen C; Studd JW
Maturitas; 1999 Nov; 33 Suppl 1():S73-81. PubMed ID: 10661618
[TBL] [Abstract][Full Text] [Related]
18. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome.
Smith RN; Studd JW; Zamblera D; Holland EF
Br J Obstet Gynaecol; 1995 Jun; 102(6):475-84. PubMed ID: 7632640
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of a low-dose of Oesclim (25 mcg daily) in the management of symptomatic menopausal women: a French open-label study.
Elia D; Tamborini A; Leocmach Y; Chadha-Boreham H
Curr Med Res Opin; 2000; 16(2):94-106. PubMed ID: 10893653
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system.
Raynaud JP; Lévrier M; Calaf J; Laur C; Pélissier C
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):309-18. PubMed ID: 15860275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]